Flector
(Diclofenac epolamine)Phase 3Small molecule
Flector is one of 22 small molecule programs targeting Sprain. It is currently in Phase 3.
1
Indications
3
Total Trials
0
Active Trials
21
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
40 competitors in Sprain
#DrugCompanyPhaseTrials
1Voltaren
NovartisApproved
Zyloprim
Alnylam PharmaceuticalsApproved
Keflex
Eli LillyApproved
Oruvail
WWyeth-Lederle Vaccines
Approved
Bextra
TThe Searle Company Limited Pakistan
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Indocin
LLife Extension Foundation Inc.
Approved
Vioxx
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Tylenol
KKenvue Brands
Approved
Advil
KKenvue Brands
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jan 31, 2007
FLECTOR
NDA NDA021234
Dec 19, 2018
LICART
NDA NDA206976
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diclofenac epolamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]